HIV |
3DS1+Bw4 80l |
Delayed progression towards AIDS |
47 |
3DS1+Bw4 80l |
Protection from opportunistic infections |
60 |
3DS1 homozygous |
Reduced risk of acquisition of infection in HIV exposed individuals |
61 |
3DS1+ Bw4 |
Increased in HIV exposed seronegative |
62 |
3DS1+Bw4+3DL1 |
Increased KIR3DS1 gene copy number associated with lower viral set point. |
53 |
HBV |
3DS1 |
Associated with spontaneous recovery |
63 |
HCV |
3DS1 homozygous + Bw4 |
Increased risk of cirrhosis |
64 |
3DS1+Bw4 80l |
Decreased risk of hepatocellular carcinoma |
65 |
Tuberculosis |
3DS1+Bw4 80l |
Decreased susceptibility |
66 |
Cervical neoplasia |
3DS1+ Bw4 |
Increased risk |
67 |
Multiple Myeloma |
3DS1 |
Decreased progression-free survival after autologous stem cell transplantation |
68 |
Endometriosis |
3DS1 |
Reduced susceptibility |
69 |
Ankylosing Spondylitis |
3DS1 |
Increased susceptibility |
70,71
|
3DS1 |
No effect |
72 |
3DS1+Bw4 80l |
Increased susceptibility |
73 |
HSCT |
3DS1 (donor) |
Decreased acute GvHD |
74 |
Functional |
|
|
|
HIV |
Increased inhibition of viral production by 3DS1+ NK cells in Bw4 80I patients. Preferential activation of KIR3DS1+ cells upon exposure to HIV+ Bw4 80I+ cells |
51 |
Expansion of KIR3DS1+ NK cells in acute HIV infection |
52 |
Increased IFN-γ production and CD107a levels in 3DS1+ donors at baseline and after stimulation with class I negative target cells. Not associated with Bw4 80I |
75 |